OIPE IAP68 DEC 03 2007 PATENT & TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/085001
		Serial No.	10/682,612
		Applicant	Stockfleth
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	October 9, 2003
		Group	1655
(37 C.F.R. § 1.98(b))		IDS Filed	November 29, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
WM	Wang et al., "Inhibitory Effects of Black Tea, Green Tea, Decaffeinated Black Tea, and Decaffeinated Green Tea on Ultraviolet B Light-Induced Skin Carcinogenesis in 7,12-Dimethylbenz[α]Anthracene-Initiated SKH-1 Mice," Cancer Research 54:3428-.3435 (1994).

EXAMINER	DATE CONSIDERED 1/28/08

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

OIPE IAP87
NOV 07 2007
PATENT & TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/085001
	Serial No.	10/682,612
	Applicant	Stockfleth
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Filing Date	October 9, 2003
	Group	1655
(37 C.F.R. § 1.98(b))	IDS Filed	November 5, 2007

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
AWM	4,863,970	09/1989	Patel et al.
	5,910,308	06/1999	Arthur H.K. D'Jang
	6,337,320	01/2002	Hersh et al.
	2002/0151582	10/2002	Dou et al.
	2002/0031535	03/2002	Sheffield, Felix
	2003/0143165	07/2003	Evans et al.,
	2004/0181130	09/2004	Miller et al.
	2004/0191842	09/20/04	Hsu et al.
	5,633,284	05/27/97	Meyer
	4,002,775	01/11/77	Kabara
	6,576,660	06/10/03	Shutsung et al.
	6,696,484	02/24/04	Liao et al.
	6,372,234	04/16/02	Deckers et al.
	5,652,266	07/29/97	Bobier-Rival et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
AWM	WO 00/33832	06/15/00	PCT	
	WO 00/29027	05/25/00	PCT	
	WO 99/66897	12/29/99	PCT	
	WO 98/20872	05/22/98	PCT	
	EP 1 005 862 A1	06/07/00	Europe	

EXAMINER	DATE CONSIDERED 1/18/08

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/085001
	Serial No.	10/682,612
	Applicant	Stockfleth
	Filing Date	October 9, 2003
	Group	1655
	IDS Filed	November 5, 2007

U.S. PATENT DOCUMENTS				
	EP 0 842 660 A1	05/20/98	Europe	
MM	EP 0 087 161	08/31/83	Europe	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
MM	Linden et al., "Chemoprevention of Nonmelanoma Skin Cancer: Experience with a Polyphenol from Green Tea," *Recent Results in Cancer Research* 163:165-171 (2003).
	Katiyar et al., "Green Tea and Skin," *Arch Dermatol.* 136:989-994 (2000).
	Zhao et al., "Photoprotection in Human Skin by Green Tea and Black Tea," Proceeding of the American Association for Cancer Research 39:382 (1998).
	Beutner et al. "Treatment of Genital Warts with an Immune-Response Modifier (Imiquimod)," *Journal of the American Academy of Dermatology* 38:230-239 (1998).
	Ceve, "Drug Delivery Across the Skin," *Exp. Opin. Invest. Drugs* 6:1887-1937 (1997).
	Diding et al., "Isopropyl Myristate as Solvent in Sterility Testing of Petrolatum-Based Ointments," pp. 616-621 (Chemical Abstract 19503q) (1973).
	Edwards et al., "Self-Administered Topical 5% Imiquimod Cream for External Anogenital Warts," *Arch. Dermatol.* 134:25-30 (1998).
	Kristmundsdottir et al., "Development and Evaluation of Microbicidal Hydrogels Containing Monoglyceride as the Active Ingredient," *Journal of Pharmaceutical Sciences* 88:1011-1015 (1999).
	Sands et al., "Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols," *Antimicrobial Agents and Chemotherapy* 15:67-73 (1979).
	Handbook of Pharmaceutical Excipients, published by (1986) American Pharmaceutical Association and the Pharmaceutical Society of Great Britain pp. 148
	Garg S. et al., Compendium of Pharmaceutical Excipients for Vaginal Formulations," Pharmaceutical Technology Drug Delivery pp. 14-24 (2001).
	CIR Compendium 1995, Page 88 (Abstract).
	Chemical Abstracts (1974), 80:p. 319 (1974).

EXAMINER	DATE CONSIDERED 1/8/08.

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

O.I.P.E. JC1
NOV 20 2003
PATENT & TRADEMARK

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/085001
	Serial No.	10/682,612
	Applicant	Eggert Stockfleth
	Filing Date	October 9, 2003
	Group	
	IDS Filed	November 18, 2003

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	4,248,789	02/03/81	Okada			
	4,673,530	06/16/87	Hara			
	4,613,672	09/23/86	Hara			
	4,913,909	04/03/90	Hara et al.			
	6,096,359	08/01/00	Bombardelli et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

EXAMINER [signature] DATE CONSIDERED 1/18/08

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

OIPE
FEB 2 2 2005
PATENT & TRADEMARK OFFICE

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/085001
	Serial No.	10/682,612
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Eggert Stockfleth
	Filing Date	October 9, 2003
	Group	1632
(37 C.F.R. § 1.98(b))	IDS Filed	02/17/05

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,613,672	9/23/86	Hara			
	4,673,530	6/16/87	Hara			
	4,913,909	4/3/90	Hara et al.			
	5,104,901	4/14/92	Shimamura et al.			
	5,135,957	8/4/92	Shimamura			
	5,137,922	8/11/92	Shimamura et al.			
	5,204,089	4/20/93	Hara et al.			
	5,318,986	6/7/94	Hara et al.			
	5,358,713	10/25/94	Shimamura			
	5,470,565	11/28/95	Hayakawa et al.			
	5,670,154	9/23/97	Hara et al.			
	5,747,053	5/5/98	Nashimoto et al.			
	5,766,595	6/16/98	Yamane et al.			
	5,795,911	8/18/98	Cheng et al.			
	5,804,567	9/8/98	Cheng et al.			
	5,807,564	9/15/98	Shimamura et al.			
	5,888,527	3/30/99	Nashimoto et al.			
	5,968,973	10/19/99	Cheng et al.			
	6,197,808	3/6/01	Cheng et al.			
	6,248,346	6/19/01	Hara et al.			
	2002/0006447	1/17/02	Yamazaki et al.			

EXAMINER	DATE CONSIDERED 1/18/08

EXAMINER: Initial citation considered. Draw line through citation if ~~not in conformance~~ and not considered. Include copy of this form with the next communication to applicant.

OIPE SC1617
JUL 29 2005
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50125/085001
		Serial No.	10/682,612
		Applicant	Eggert Stockfleth
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	October 9, 2003
		Group	1632
(37 C.F.R. § 1.98(b))		IDS Filed	07/27/05

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
MM	US 2003/0166583	09/04/03	Yoa-Pu Hu et al.			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MM	WO 01/51048	07/19/01	WIPO			
	WO 04/026323	04/01/04	WIPO			
	WO 04/053097	06/24/04	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
MM	Cao et al., "Angiogenesis Inhibited By Drinking Tea," *Nature* 398: 381 (1999).
	Linden et al., "Chemoprevention of Non-Melanoma Skin Cancer: Experience with a Polyphenol From Green Tea," *European Journal of Cancer* 38: S24 (2002).
	Linden et al., "Epigallocatechin Gallate in the Chemoprevention of Non-Melanoma Skin Cancer, with Biomarker Studies of Actinic Keratoses, Sun-Damaged, and Non Sun-Damaged Skin: Results of a Clinical Trial," *Frontiers in Cancer Prevention Research* A113: 29 (2003).
	McCarty " Polyphenol-mediated Inhibition of AP-1 Transactivating Activity May Slow Cancer Growth By Impeding Angiogensis and Tumor Invasiveness," *Medical Hypothesis* 50: 511-514 (1998) (XP-000957651).
	Mukhtar et al., "Green Tea Polyphenols Induce Apoptosis and Alter the Progression of Cell Cycle in Human Epidermoid Carcinoma Cells A431," *Proceedings of the American Association for Cancer Research and American Society of Clinical Oncology* 38: 580 (1997) (XP-000997348).
	Proniuk et al., " Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention," *Journal of Pharmaceutical Sciences* 91: 111-116 (2002) (XP- 002270297).
	Zhu et al., "Study of Tea Polyphenol as a Reversal Agent for Carcinoma Cell Lines' Multidrug Resistance(Study of TP as a MDR Reversal Agent)," *Nuclear Medicine and Biology* 28: 735-740 (2001).
EXAMINER	DATE CONSIDERED 1/18/08.
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	